Comparison 7. Sensitivity analyses for clinical guidelines.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 7.1 Excluding clinical guidelines with unclear or undisclosed financial conflicts of interest | 1 | Risk Ratio (IV, Random, 95% CI) | 1.08 [0.71, 1.64] | |
| 7.2 Excluding clinical guidelines with neutral recommendations | 1 | Risk Ratio (IV, Random, 95% CI) | 1.08 [0.71, 1.64] | |
| 7.3 Excluding all studies of clinical guidelines which disclosed a relevant conflict of interest of study authors | 3 | Risk Ratio (IV, Random, 95% CI) | 1.23 [0.90, 1.69] | |
| 7.4 Re‐analysing our primary analyses using fixed‐effect meta‐analyses | 4 | Risk Ratio (IV, Fixed, 95% CI) | 1.26 [0.93, 1.69] | |
| 7.5 Re‐categorising financial conflicts of interest into financial conflicts of interest related to the manufacturer | 1 | Risk Ratio (IV, Random, 95% CI) | 1.08 [0.71, 1.64] | |
| 7.6 Re‐categorising financial conflicts of interest into financial conflicts of interest related to any for‐profit company | 3 | Risk Ratio (IV, Random, 95% CI) | 1.46 [0.96, 2.21] |